Propionibacterium Acnes Clinical Trial
Official title:
Does Hydrogen Peroxide Skin Preparation Reduce Propionibacterium Acnes in Shoulder Arthroplasty?
NCT number | NCT03057821 |
Other study ID # | 96964 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | January 2017 |
Est. completion date | March 2019 |
Verified date | August 2019 |
Source | University of Utah |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigator's plan to determine whether pre-operative skin preparation with hydrogen peroxide alters rates of P acnes culture positivity. They hypothesize that pre-operative skin preparation with hydrogen peroxide will reduce rates of P acnes culture positivity.
Status | Completed |
Enrollment | 62 |
Est. completion date | March 2019 |
Est. primary completion date | March 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 90 Years |
Eligibility |
Inclusion Criteria: - Patients undergoing primary shoulder arthroplasty Exclusion Criteria: - Patients with prior shoulder surgery. - Patients with a symptomatic infection or history of infection, recent antibiotic use (within six weeks), or with clinical signs of infection such as an elevated ESR, CRP, positive aspiration cultures, or positive biopsy. - Patients with a known hypersensitivity to hydrogen peroxide. |
Country | Name | City | State |
---|---|---|---|
United States | University of Utah Orthopaedic Center | Salt Lake City | Utah |
Lead Sponsor | Collaborator |
---|---|
University of Utah |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Positive P acnes culture | The primary outcome of the study will be P acnes culture positive results. | 2-weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04021524 -
BPO vs Hibiclens Soap for Surgical Preparation
|
Phase 4 | |
Completed |
NCT00211523 -
Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne
|
Phase 2 | |
Completed |
NCT00211497 -
Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne
|
Phase 2 |